Evidence map›Paper›PMID 35702670›Full record

ArticleNeuro-oncology advances

Pleiotropic

Kyle M Walsh, Chenan Zhang, Lisa Calvocoressi, Helen M Hansen, Andrew Berchuck, Joellen M Schildkraut, Melissa L Bondy, Margaret Wrensch, Joseph L Wiemels, Elizabeth B Claus

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Kyle M WalshDepartment of Neurosurgery and Duke Cancer Institute, Duke University School of Medicine. Durham, North Carolina, USA.
Chenan ZhangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Lisa CalvocoressiSchool of Public Health, Yale University, New Haven, Connecticut, USA.
Helen M HansenDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Andrew BerchuckDepartment of Obstetrics and Gynecology and Duke Cancer Institute, Duke University School of Medicine. Durham, North Carolina, USA.
Joellen M SchildkrautRollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Melissa L BondyDepartment of Epidemiology and Population Health, Stanford University, Palo Alto, California, USA.
Margaret WrenschDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Joseph L WiemelsCenter for Genetic Epidemiology, University of Southern California, Los Angeles, California, USA.
Elizabeth B ClausSchool of Public Health, Yale University, New Haven, Connecticut, USA.
University of California, San Francisco · USYale University · USDuke University · USEmory University · USNeurological Surgery · USStanford University · USUniversity of Southern California · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Medical Research Council MC_PC_17228Medical Research Council MC_QA137853NCATS NIH HHS UL1 TR001863NCI NIH HHS T32 CA151022
6 · The paper itself

Abstract

Background: Risk of tumors of the breast, ovary, and meninges has been associated with hormonal factors and with one another. Genome-wide association studies (GWAS) identified a meningioma risk locus on 10p12 near previous GWAS hits for breast and ovarian cancers, raising the possibility of genetic pleiotropy. Methods: We performed imputation-based fine-mapping in three case-control datasets of meningioma (927 cases, 790 controls), female breast cancer (28 108 cases, 22 209 controls), and ovarian cancer (25 509 cases, 40 941 controls). Analyses were stratified by sex (meningioma), estrogen receptor (ER) status (breast), and histotype (ovarian), then combined using subset-based meta-analysis in ASSET. Lead variants were assessed for association with additional traits in UK Biobank to identify potential effect-mediators. Results: Two-sided subset-based meta-analysis identified rs7084454, an expression quantitative trait locus (eQTL) near the Conclusions: We identify a

Indexed as

breast cancermeningiomaMLLT10ovarian cancerpleiotropy

Identifiers

PMID35702670
PMCPMC9187056
OpenAlexW4223946952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.